PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.




PMID- 29277771
OWN - NLM
STAT- In-Process
LR  - 20171226
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 38
IP  - 1
DP  - 2018 Jan
TI  - Effects of siRNA Silencing of TUG1 and LCAL6 Long Non-coding RNAs on
      Patient-derived Xenograft of Non-small Cell Lung Cancer.
PG  - 179-186
AB  - BACKGROUND/AIM: The aim of the present study was to establish a patient-derived
      xenograft (PDX) mouse model of non-small cell lung cancer (NSCLC) and investigate
      the anti-tumor efficacy of silencing of TUG1 and LCAL6 long non-coding RNA in the
      PDX model. MATERIALS AND METHODS: PDXs were established by subcutaneously
      implanting NSCLC surgical tumor fragments into immunodeficient mice. PDX
      characterization was performed by histopathological, immunohistochemical and
      real-time polymerase chain reaction (RT-PCR) analyses for NSCLC subtype-specific 
      markers and expression of LCAL6 and TUG1. Anti-tumor efficacy of siRNA silencing 
      of TUG1 and LCAL6 was also investigated in the PDX model. The effect of TUG1 and 
      LCAL6 silencing on protein expression of proliferation marker Ki67 and HOX-gene
      family HOXB7 in the tumors was assessed by immunohistochemical staining and
      Western blotting. RESULTS: Establishment of NSCLC PDX models resulted in 9 of 26 
      cases (34.6%). Lung squamous cell carcinomas (SCC) had a higher engraftment rate 
      (58.3%) than lung adenocarcinomas (ADC) (18.2%) (p<0.05). Comparative analysis
      indicated these established PDX models of NSCLC closely resembled the original
      tumors with regard to NSCLC subtype-specific markers TTF-1, napsin A, p63 and
      expression of LCAL6 and TUG1. The tumor volume and weight were significantly
      reduced in the TUG1-silenced group as compared to the control group (p<0.05).
      However, no significant tumor growth inhibition was found in the LCAL6-silenced
      group (p>0.05). Expression of both TUG1and LCAL6 was reduced by siRNA treatment. 
      Expression of Ki67 and HOXB7 was significantly suppressed in both the TUG1- and
      LCAL6-silenced groups compared to the control group (p<0.01). The TUG1-silenced
      group showed more reduced Ki67 expression than the LCAL6-silenced group (p<0.05).
      CONCLUSION: PDX NSCLC models were established with a high degree of similarity
      with the original tumor with regard to histological, immunohistochemical features
      and RNA expression of TUG1 and LCAL6. Silencing of TUG1 inhibited both tumor
      growth and expression of the proliferation marker Ki67 and HOX-gene family HOXB7 
      in the PDX model of NSCLC.
CI  - Copyright(c) 2018, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Fang, Tian
AU  - Fang T
AD  - Department of Comparative Medicine, Jinling Hospital, Clinical School of Medical 
      College of Nanjing University, Nanjing, P.R. China.
FAU - Huang, Hairong
AU  - Huang H
AD  - Department of Cardiothoracic Surgery, Jinling Hospital, Clinical School of
      Medical College of Nanjing University, Nanjing, P.R. China.
FAU - Li, Xiaoyou
AU  - Li X
AD  - Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Affiliated Cancer 
      Hospital of Nanjing Medical University, Nanjing, P.R. China.
FAU - Liao, Jing
AU  - Liao J
AD  - Origin Biosciences Inc., Nanjing, P.R. China.
FAU - Yang, Zhijian
AU  - Yang Z
AD  - Origin Biosciences Inc., Nanjing, P.R. China.
AD  - AntiCancer Inc., San Diego, CA, U.S.A.
FAU - Hoffman, Robert M
AU  - Hoffman RM
AD  - AntiCancer Inc., San Diego, CA, U.S.A.
AD  - Department of Surgery, University of California, San Diego, CA, U.S.A.
FAU - Cheng, X I
AU  - Cheng XI
AD  - Department of Cardiothoracic Surgery, Jinling Hospital, Clinical School of
      Medical College of Nanjing University, Nanjing, P.R. China.
FAU - Liang, Lei
AU  - Liang L
AD  - Department of Comparative Medicine, Jinling Hospital, Clinical School of Medical 
      College of Nanjing University, Nanjing, P.R. China.
FAU - Hu, Wenjuan
AU  - Hu W
AD  - Department of Comparative Medicine, Jinling Hospital, Clinical School of Medical 
      College of Nanjing University, Nanjing, P.R. China.
FAU - Yun, Shifeng
AU  - Yun S
AD  - Department of Comparative Medicine, Jinling Hospital, Clinical School of Medical 
      College of Nanjing University, Nanjing, P.R. China [email protected]
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
OTO - NOTNLM
OT  - lung cancer
OT  - patient-derived xenograft
OT  - siRNA
EDAT- 2017/12/27 06:00
MHDA- 2017/12/27 06:00
CRDT- 2017/12/27 06:00
PHST- 2017/10/10 00:00 [received]
PHST- 2017/10/31 00:00 [revised]
PHST- 2017/11/01 00:00 [accepted]
PHST- 2017/12/27 06:00 [entrez]
PHST- 2017/12/27 06:00 [pubmed]
PHST- 2017/12/27 06:00 [medline]
AID - 38/1/179 [pii]
PST - ppublish
SO  - Anticancer Res. 2018 Jan;38(1):179-186.